Hemato-oncology
Within the hemato-oncology department of the Princess Máxima Center, specialized care and leading scientific research go hand in hand. What we discover in the laboratory today is made available to patients as quickly as possible. This bridge between scientific innovation and optimal care is at the core of our department.
Contact
Josef Vormoor
Pediatric oncologist, Clinical director hemato-oncolody
We treat all children in the Netherlands with malignant diseases of the blood and lymph nodes, as well as several forms of bone marrow failure. For specific, highly specialized treatment pathways, international patients also come to our center.
Our strength lies in broad clinical expertise combined with in-depth specialist knowledge. We have international experts in every subfield of hematologic disorders and are at the forefront of molecular diagnostics and innovative (immune) therapies. In addition, we play an active international role in early-phase clinical trials, enabling new treatment strategies to become available more quickly for children who urgently need them.
Our medical team is complemented by paramedical experts, including specialists in pediatric psychology, dietetics, physical therapy and rehabilitation.
Patient population and care portfolio
Within hemato-oncology (including stem cell transplantation), we treat each year, among others:
Acute lymphoblastic leukemia (ALL): approximately 110 children per year
Myeloid malignancies (AML/MDS/CML): approximately 40 children per year
Histiocytoses: approximately 20–30 children per year
Lymphomas: approximately 70–80 children per year
Immunotherapy and stem cell transplantation: approximately 50 allogeneic transplants per year and 10–15 CAR T-cell treatments
We also provide gene therapy and stem cell transplantation for children with bone marrow failure and metabolic disorders.
Team and organization
The clinical hemato-oncology team (excluding the SCT team) consists of:
13 clinical specialists
11 nurse specialists
5 academic positions
Collaboration between disciplines is structurally embedded in both the care pathways and the design and execution of clinical studies.